Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?Zacks Investment Research • Friday
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40InvestorPlace • Wednesday
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/09/24
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 06/26/24
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell DiseaseGlobeNewsWire • 06/14/24
Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?Zacks Investment Research • 06/06/24
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressGlobeNewsWire • 05/14/24
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceGlobeNewsWire • 05/08/24
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial ResultsGlobeNewsWire • 05/07/24
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 05/01/24
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?Zacks Investment Research • 03/28/24
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 03/26/24